Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the chronic spontaneous urticaria market grown in recent years?

The chronic spontaneous urticaria market has experienced significant growth in recent years. It is expected to grow from $2.06 billion in 2024 to $2.23 billion in 2025, at a compound annual growth rate (CAGR) of 8.6%. This growth can be attributed to advancements in diagnostic tools, rising awareness among healthcare providers, patient support groups, ongoing research and clinical trials exploring new treatments, and increasing healthcare spending.

How is the chronic spontaneous urticaria market size expected to evolve during the forecast period?

The chronic spontaneous urticaria market is projected to grow to $3.08 billion by 2029 at an 8.4% CAGR. This growth is driven by a higher number of diagnosed cases, expanding patient pools, and better healthcare infrastructure. Trends include innovations in technology, advancements in biological therapies, personalized medicine, telemedicine, AI, and machine learning, as well as increasing drug approvals.

Get your chronic spontaneous urticaria market report here!

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which key drivers are propelling the chronic spontaneous urticaria market’s growth?

Increasing alcohol consumption is expected to propel the growth of the chronic spontaneous urticaria market. Rising alcohol consumption, driven by social norms and stress, can exacerbate symptoms of chronic spontaneous urticaria, such as swelling and hives. According to rehabs.UK, 55% of men and 41% of women reported weekly alcohol consumption in 2024. With increased alcohol-related hospital admissions, the demand for treatments for chronic spontaneous urticaria is rising. As alcohol consumption continues to rise, it is driving the growth of the chronic spontaneous urticaria market.

What are the market segments in the chronic spontaneous urticaria industry?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

Which leading companies are shaping the growth of the chronic spontaneous urticaria market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

What key trends are currently impacting the chronic spontaneous urticaria market’s development?

Companies in the chronic spontaneous urticaria market are developing next-generation treatments like Briquilimab (JSP191) to enhance efficacy and reduce dosing frequency. Briquilimab is a monoclonal antibody that targets CD47 to treat chronic spontaneous urticaria. For example, in November 2023, US-based Jasper Therapeutics dosed its first patient in a Phase 1b/2a clinical trial to evaluate Briquilimab’s safety and effectiveness for chronic spontaneous urticaria, aiming to improve symptoms and quality of life for patients with this condition.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

Which geographic areas are influencing the growth of the chronic spontaneous urticaria market?

North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Chronic Lower Back Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-lower-back-pain-global-market-report

Chronic Pain Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Cough Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: